Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor

被引:43
作者
Nakataki, E
Yano, S
Matsumori, Y
Goto, H
Kakiuchi, S
Muguruma, H
Bando, Y
Uehara, H
Hamada, H
Kito, K
Yokoyama, A
Sone, S
机构
[1] Univ Tokushima, Grad Sch, Dept Internal Med & Mol Therapeut, Tokushima 7708503, Japan
[2] Univ Tokushima, Grad Sch, Dept Mol & Environm Pathol, Tokushima 7708503, Japan
[3] Ehime Univ, Sch Med, Dept Pathol, Toon, Ehime 17910295, Japan
[4] Ehime Univ, Sch Med, Dept Internal Med 2, Toon, Ehime 17910295, Japan
[5] Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol & Internal Med, Minami Ku, Hiroshima 7348551, Japan
来源
CANCER SCIENCE | 2006年 / 97卷 / 03期
关键词
D O I
10.1111/j.1349-7006.2006.00163.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant pleural mesothelioma (MPM) is closely related to exposure to asbestos, and a rapid increase in the number of MPM patients in Japan is estimated in the years 2010-2050. The purpose of the present study was to establish a clinically relevant animal model that shows human patient-like progression of MPM. Here, we demonstrate that a human MPM cell line (EHMES-10) inoculated orthotopically (thoracic cavity) into severe combined immunodeficiency (SCID) mice produces highly vascularized thoracic tumors with pleural dissemination and bloody pleural effusions by 5 weeks, suggesting a patient-like progression of this cell line after orthotopic inoculation. EHMES-10 cells overexpressed vascular endothelial growth factor (VEGF), a molecule responsible for malignant effusions, and its receptor. Treatment with cisplatin, but not gemcitabine, significantly inhibited the production of pleural effusions, but it was not effective for thoracic tumors, consistent with chemotherapy refractory characteristics of MPM in patients. Our patient-like orthotopic model using EHMES-10 cells overexpressing VEGF and its receptor may be useful for examining the molecular pathogenesis of MPM and may contribute to the development of novel treatment strategies for MPM.
引用
收藏
页码:183 / 191
页数:9
相关论文
共 44 条
[1]  
Broaddus VC, 1997, AM J RESP CELL MOL, V17, P657
[2]   Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study [J].
Byrne, MJ ;
Davidson, JA ;
Musk, AW ;
Dewar, J ;
van Hazel, G ;
Buck, M ;
de Klerk, NH ;
Robinson, BWS .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :25-30
[3]  
Colt HG, 1996, ANTICANCER RES, V16, P633
[4]   Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration [J].
Dias, S ;
Hattori, K ;
Zhu, ZP ;
Heissig, B ;
Choy, M ;
Lane, W ;
Wu, Y ;
Chadburn, A ;
Hyjek, E ;
Gill, M ;
Hicklin, DJ ;
Witte, L ;
Moore, MAS ;
Rafii, S .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (04) :511-521
[5]   Mineral fiber content of lungs in patients with mesothelioma seeking compensation in Quebec [J].
Dufresne, A ;
Begin, R ;
Churg, A ;
Masse, S .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (02) :711-718
[6]  
Ferrara N, 1997, TUMOUR ANGIOGENESIS, P185
[7]   Critical determinants of metastasis [J].
Fidler, IJ .
SEMINARS IN CANCER BIOLOGY, 2002, 12 (02) :89-96
[8]  
FU XY, 1993, ANTICANCER RES, V13, P901
[9]   A METASTATIC NUDE-MOUSE MODEL OF HUMAN PANCREATIC-CANCER CONSTRUCTED ORTHOTOPICALLY WITH HISTOLOGICALLY INTACT PATIENT SPECIMENS [J].
FU, XY ;
GUADAGNI, F ;
HOFFMAN, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (12) :5645-5649
[10]  
FURUKAWA T, 1993, CANCER RES, V53, P1204